These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 35582035)

  • 1. Statins and endocrine resistance in breast cancer.
    Hyder T; Marti JLG; Nasrazadani A; Brufsky AM
    Cancer Drug Resist; 2021; 4(2):356-364. PubMed ID: 35582035
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulatory effects of statins on Akt signaling for prevention of cancers.
    Hosseini FS; Ahmadi A; Kesharwani P; Hosseini H; Sahebkar A
    Cell Signal; 2024 Aug; 120():111213. PubMed ID: 38729324
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endocrine resistance in breast cancer: focus on the phosphatidylinositol 3-kinase/akt/mammalian target of rapamycin signaling pathway.
    Hasson SP; Rubinek T; Ryvo L; Wolf I
    Breast Care (Basel); 2013 Aug; 8(4):248-55. PubMed ID: 24415977
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simvastatin-induced breast cancer cell death and deactivation of PI3K/Akt and MAPK/ERK signalling are reversed by metabolic products of the mevalonate pathway.
    Wang T; Seah S; Loh X; Chan CW; Hartman M; Goh BC; Lee SC
    Oncotarget; 2016 Jan; 7(3):2532-44. PubMed ID: 26565813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting the PI3K/AKT/mTOR pathway in estrogen receptor-positive breast cancer.
    Ciruelos Gil EM
    Cancer Treat Rev; 2014 Aug; 40(7):862-71. PubMed ID: 24774538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Potential of Isoprenoids in Adjuvant Cancer Therapy to Reduce Adverse Effects of Statins.
    Mo H; Jeter R; Bachmann A; Yount ST; Shen CL; Yeganehjoo H
    Front Pharmacol; 2018; 9():1515. PubMed ID: 30662405
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Statins: a role in breast cancer therapy?
    Borgquist S; Bjarnadottir O; Kimbung S; Ahern TP
    J Intern Med; 2018 Oct; 284(4):346-357. PubMed ID: 29923256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase.
    Fu X; Creighton CJ; Biswal NC; Kumar V; Shea M; Herrera S; Contreras A; Gutierrez C; Wang T; Nanda S; Giuliano M; Morrison G; Nardone A; Karlin KL; Westbrook TF; Heiser LM; Anur P; Spellman P; Guichard SM; Smith PD; Davies BR; Klinowska T; Lee AV; Mills GB; Rimawi MF; Hilsenbeck SG; Gray JW; Joshi A; Osborne CK; Schiff R
    Breast Cancer Res; 2014 Sep; 16(5):430. PubMed ID: 25212826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overcoming endocrine resistance in hormone receptor-positive breast cancer.
    AlFakeeh A; Brezden-Masley C
    Curr Oncol; 2018 Jun; 25(Suppl 1):S18-S27. PubMed ID: 29910644
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.
    McCubrey JA; Steelman LS; Abrams SL; Lee JT; Chang F; Bertrand FE; Navolanic PM; Terrian DM; Franklin RA; D'Assoro AB; Salisbury JL; Mazzarino MC; Stivala F; Libra M
    Adv Enzyme Regul; 2006; 46():249-79. PubMed ID: 16854453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The isomiR-140-3p-regulated mevalonic acid pathway as a potential target for prevention of triple negative breast cancer.
    Bhardwaj A; Singh H; Trinidad CM; Albarracin CT; Hunt KK; Bedrosian I
    Breast Cancer Res; 2018 Dec; 20(1):150. PubMed ID: 30537987
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The proteasome inhibitor Bortezomib (Velcade) as potential inhibitor of estrogen receptor-positive breast cancer.
    Thaler S; Thiede G; Hengstler JG; Schad A; Schmidt M; Sleeman JP
    Int J Cancer; 2015 Aug; 137(3):686-97. PubMed ID: 25530422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blockage of the mevalonate pathway overcomes the apoptotic resistance to MEK inhibitors with suppressing the activation of Akt in cancer cells.
    Iizuka-Ohashi M; Watanabe M; Sukeno M; Morita M; Hoang NTH; Kuchimaru T; Kizaka-Kondoh S; Sowa Y; Sakaguchi K; Taguchi T; Sakai T
    Oncotarget; 2018 Apr; 9(28):19597-19612. PubMed ID: 29731968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interconnection of Estrogen/Testosterone Metabolism and Mevalonate Pathway in Breast and Prostate Cancers.
    Mokarram P; Alizadeh J; Razban V; Barazeh M; Solomon C; Kavousipour S
    Curr Mol Pharmacol; 2017; 10(2):86-114. PubMed ID: 26758947
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting HMG-CoA reductase with statins in a window-of-opportunity breast cancer trial.
    Bjarnadottir O; Romero Q; Bendahl PO; Jirström K; Rydén L; Loman N; Uhlén M; Johannesson H; Rose C; Grabau D; Borgquist S
    Breast Cancer Res Treat; 2013 Apr; 138(2):499-508. PubMed ID: 23471651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PI3K/AKT/mTOR pathway activation in primary and corresponding metastatic breast tumors after adjuvant endocrine therapy.
    Beelen K; Hoefnagel LD; Opdam M; Wesseling J; Sanders J; Vincent AD; van Diest PJ; Linn SC
    Int J Cancer; 2014 Sep; 135(5):1257-63. PubMed ID: 24501006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of 3-hydroxy-3-methylglutaryl-CoA reductase mediates statin resistance in breast cancer cells.
    Göbel A; Breining D; Rauner M; Hofbauer LC; Rachner TD
    Cell Death Dis; 2019 Jan; 10(2):91. PubMed ID: 30692522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative efficacy and safety of CDK4/6 and PI3K/AKT/mTOR inhibitors in women with hormone receptor-positive, HER2-negative metastatic breast cancer: a systematic review and network meta-analysis.
    Han Y; Wang J; Wang Z; Xu B
    Curr Probl Cancer; 2020 Dec; 44(6):100606. PubMed ID: 32446638
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation of PI3K/Akt signaling and hormone resistance in breast cancer.
    Tokunaga E; Kimura Y; Mashino K; Oki E; Kataoka A; Ohno S; Morita M; Kakeji Y; Baba H; Maehara Y
    Breast Cancer; 2006; 13(2):137-44. PubMed ID: 16755107
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integrin β1, myosin light chain kinase and myosin IIA are required for activation of PI3K-AKT signaling following MEK inhibition in metastatic triple negative breast cancer.
    Choi C; Kwon J; Lim S; Helfman DM
    Oncotarget; 2016 Sep; 7(39):63466-63487. PubMed ID: 27563827
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.